Anti-proteasome autoantibodies represent specific diagnostic markers for autoimmune myositis and SLE

Journal/Book: Z Rheumatol 1998; 57 Suppl. 1: 38 (F 50). 1998;

Abstract: 1Charité Dept. Med. III Institute of Biochemistry Humboldt University of Berlin The proteasome complex involved in MHC class I restricted antigen generation has been identified as a target of humoral immune response in patients with autoimmune myositis and SLE. To investigate a possible role of proteasomes in other autoimmune diseases anti-proteasome antibodies were analyzed in sera from various rheumatic patients from patients with diabetes mellitus type I solid tumors and healthy controls. Analysis of the B-cell response against human 20S proteasomes was performed by using ELISA immunoblot and two-dimensional non-equilibrium pH gradient electrophoresis (NEPHGE). Anti-proteasome antibodies were detected in 60 % (23/39) of patients with poly/dermatomyositis in 57 % (34/60) of patients with SLE and in 39 % (17/43) of patients with Sjögren's syndrome. These frequencies significantly exceeded those found in the sera from patients with diabetes mellitus type I (6/60 p < 0.001) rheumatoid arthritis (1/47 p < 0.001) and tumor patients (8/49 p < 0.008). 80 healthy controls did not exhibit anti-proteasome reactivity. Of note follow-up analysis revealed a correlation between anti-proteasome titers and the diseases activity in patients with autoimmune myositis (CK-values) and in SLE-patients (anti-dsDNA antibodies). Anti-proteasome antibodies represent specific diagnostic markers for autoimmune myositis and SLE that also correlate with the disease activity in both entities. Moreover a significant number of patients with primary Sjögren's syndrome produce antibodies directed towards the proteasome complex. le

Zurück | Weiter